SCH772984

Catalog No.S7101

SCH772984 Chemical Structure

Molecular Weight(MW): 587.67

SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.

Size Price Stock Quantity  
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • 293T cells were transfected with Flag-WT-FBW7. Thirty hours post transfection, cells were pretreated with MG132 and various MEK/ERK inhibitors overnight before harvesting. FBW7 phosphorylation status was examined by immunoblot analysis after immunoprecipitation.

    Cell Research, 2015, 25: 561-573. SCH772984 purchased from Selleck.

    Int J Oncol, 2018, 53(2):750-760. SCH772984 purchased from Selleck.

  • K562 cells were exposed to ERK inhibitor SCH772984 (1 uM, 2 uM, 5 uM) for 48 h. Apoptosis was analyzed by Annexin V-APC labeling.

    Leuk Lymphoma 2014 1, 8. SCH772984 purchased from Selleck.

    ERK1/2 influences the effects of TGF-β1 on Cdk5 and Bax in PC12 cells. A. Original western blot showing the level of Cdk5 and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. B. Arithmetic means ± SEM (n = 4) of Cdk5 protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. C. Original western blot showing the level of Bax and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) for 2 h. D. Arithmetic means ± SEM (n = 4) of Bax protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) for 2 h. **(p < 0.01), ***(p < 0.001) indicate statistically significant difference.

    Biochem Biophys Res Commun, 2017, 485(4):775-781. SCH772984 purchased from Selleck.

Purity & Quality Control

Choose Selective ERK Inhibitors

Biological Activity

Description SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.
Features Does not directly inhibit MEK1, MEK2, BRAF, or CRAF enzyme activity.
Targets
ERK2 [1]
(Cell-free assay)
ERK1 [1]
(Cell-free assay)
1 nM 4 nM
In vitro

SCH772984 is a novel, selective and ATP competitive inhibitor of ERK1/2. SCH772984 inhibits phosphorylation of the ERK substrate p90 ribosomal S6 kinase (T359/S363 phospho-RSK) in a dose-dependent manner. SCH772984 also inhibits phosphorylation of residues in the activation loop of ERK itself. SCH772984 demonstrates EC50 values <500 nM in approximately 88% and 49% of BRAF-mutant or RAS-mutant tumor lines, respectively. Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
2P-ERK2 NFjOZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnOyTWM2OD1yLkK0JI5O MmfSNlU{PTB7M{G=
WM-266-4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrhfIt5UUN3ME2yNEBvVQ>? MmDxNlM3OTR6OUi=
UACC-62 NELoc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jyNGlEPTB;M{Cgcm0> MXKyN|YyPDh7OB?=
Colo-205 Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jFdGlEPTB;M{[gcm0> M4fuSlI{PjF2OEm4
SK-Mel-1 NHLM[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7Ee|FKSzVyPUO3JI5O NFLrN2wzOzZzNEi5PC=>
WiDr NWXESFM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TNRmlEPTB;M{mgcm0> NG\nWWIzOzZzNEi5PC=>
M14 NV;reG13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW4TWM2OD12NzDuUS=> MnnUNlM3OTR6OUi=
HT-29 NHrsNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTRfIFHUUN3ME21NEBvVQ>? NFn4e3IzOzZzNEi5PC=>
8505C NXTNcZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljlTWM2OD13MDDuUS=> M1z5T|I{PjF2OEm4
HT-144 NEfLO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLaN212UUN3ME22NEBvVQ>? MoHENlM3OTR6OUi=
SK-Mel-5 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3TTWM2OD14NjDuUS=> NYrSSJF7OjN4MUS4PVg>
A375-SM MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTd3IH7N NEe4W4czOzZzNEi5PC=>
SK-Mel-28 MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P3S2lEPTB;OEWgcm0> M1mzeFI{PjF2OEm4
LOX MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjDfFlKSzVyPUGwNEBvVQ>? NUHZPVdyOjN4MUS4PVg>
SK-Mel-3 MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrrU45KSzVyPUGxPEBvVQ>? M3W0ZVI{PjF2OEm4
K1 NGrpb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHVN3BKUUN3ME2xN|Ahdk1? NF;aWmEzOzZzNEi5PC=>
Hs-695T M{LXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnyTWM2OD1zNkWgcm0> MlvvNlM3OTR6OUi=
BHT-101 NH;kSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13SfWlEPTB;M{CwJI5O MWCyN|YyPDh7OB?=
RPMI-7951 NUTaTItyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN2NDDuUS=> NEC2[5ozOzZzNEi5PC=>
A2058 NFm1XZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTN4MDDuUS=> NFnNSlgzOzZzNEi5PC=>
SK-Hep-1 M4CyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7OVIU3UUN3ME2xOFIzKG6P NYrVPVQzOjN4MUS4PVg>
A673 NHzMNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTNyMEGgcm0> NWC5T4xJOjN4MUS4PVg>
DBTRG-05MG NWn2UoRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTGV2Y4UUN3ME2zNFAyKG6P MnjwNlM3OTR6OUi=
SW-626 NVX6R25QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;FTWM2OD1|MzDuUS=> NYHDbHBIOjN4MUS4PVg>
LoVo MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTR5IH7N M{PEN|I{PjF2OEm4
MiaPaCa M4rpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTV|IH7N MYOyN|YyPDh7OB?=
SW-620 NYC2cVBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml23TWM2OD1zMESgcm0> M33XZlI{PjF2OEm4
CAPAN-1 NULhUmxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFyNDDuUS=> MVeyN|YyPDh7OB?=
SW-527 NGH3WFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF{MTDuUS=> MWmyN|YyPDh7OB?=
HCT-116 M4m0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnJPGtKSzVyPUGyPEBvVQ>? MWiyN|YyPDh7OB?=
SW-480 M4PYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF4NTDuUS=> NG\LUWgzOzZzNEi5PC=>
HPAC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF5MDDuUS=> M3HtOFI{PjF2OEm4
OVCAR-5 M{LIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LBSWlEPTB;MkC4JI5O NIOzO2kzOzZzNEi5PC=>
AsPc-1 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXaTWM2OD1{N{Cgcm0> M1fRdlI{PjF2OEm4
A549 NYjlWYpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHxZoVKSzVyPUOyOkBvVQ>? NGTVdnMzOzZzNEi5PC=>
SNU-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTN3NDDuUS=> MV[yN|YyPDh7OB?=
HOP62 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HUNmlEPTB;Nke2JI5O MWiyN|YyPDh7OB?=
H23 NELESVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPqTWM2OD1zMECwJI5O NEjoOnczOzZzNEi5PC=>
MB-231 NYi1N|YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrlR5VFUUN3ME2xNFAxKG6P NFrudpozOzZzNEi5PC=>
SU.86.86 Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTFyMEGgcm0> MnzwNlM3OTR6OUi=
CFPAC-1 NHHtUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L2[GlEPTB;MUCwNUBvVQ>? NEK2cJczOzZzNEi5PC=>
A427 M4fkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPCN2x6UUN3ME2xOFM{KG6P MXuyN|YyPDh7OB?=
MDAH-2774 NUf1U3R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfVTWM2OD1{NkW3JI5O NU\uUVFTOjN4MUS4PVg>
NCI-H157 M3y0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTpRYRKSzVyPUOwNFAhdk1? MmTSNlM3OTR6OUi=
HTB-177 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrIVGgxUUN3ME2zNFAxKG6P Mkm4NlM3OTR6OUi=
UM-UC-3 NX;sVFRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrPc2xrUUN3ME2zNFAyKG6P NEHFcokzOzZzNEi5PC=>
HCT-8 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK0XIZKSzVyPUOwNFEhdk1? NFPFXXgzOzZzNEi5PC=>
Panc-1 NXPCUnR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP0V3pKSzVyPUOwNFEhdk1? MYWyN|YyPDh7OB?=
DLD-1 NH[2O2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj0PYtKSzVyPUOwNFEhdk1? NXLZSW1zOjN4MUS4PVg>
HCT-15 M4fIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzOc2huUUN3ME2zNFAyKG6P NH3sb44zOzZzNEi5PC=>
HL-60 M{PKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7yfGlMUUN3ME2zNEBvVQ>? Mn3ZNlM3OTR6OUi=
SK-Mel-2 NHTjUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTmU2VKSzVyPUO0JI5O M4Dnd|I{PjF2OEm4
RD M4HOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF{MzDuUS=> NETabJUzOzZzNEi5PC=>
HT-1197 NIGwbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nDbGlEPTB;M{G2JI5O NFKyc20zOzZzNEi5PC=>
Molt-3 NVPvXXZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF6yeGlKSzVyPU[wNEBvVQ>? M3[4SFI{PjF2OEm4
PA-1 M2\0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorGTWM2OD1zMECxJI5O MV:yN|YyPDh7OB?=
Molt-4 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m2R2lEPTB;M{CwNUBvVQ>? MojUNlM3OTR6OUi=
NCI-H292 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLLZZNKSzVyPUmwJI5O MofsNlM3OTR6OUi=
A2780 M4m2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\LPVBbUUN3ME2xOFMhdk1? MnzyNlM3OTR6OUi=
IGROV-1 NUTUZlNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF2NjDuUS=> NVexPXJYOjN4MUS4PVg>
SK-N-SH M{TBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjZfFlvUUN3ME2xOVAhdk1? MXmyN|YyPDh7OB?=
N-87 Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny4TWM2OD1|MEegcm0> NFnTfmozOzZzNEi5PC=>
H322 Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTN{NTDuUS=> NXTXOHdSOjN4MUS4PVg>
H716 NUnUZVZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTN|NDDuUS=> MofRNlM3OTR6OUi=
TT MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXPVoJKSzVyPUSwOkBvVQ>? M3jZe|I{PjF2OEm4
Caki-1 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTR3MDDuUS=> NYD3co5mOjN4MUS4PVg>
5637 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CxdmlEPTB;NkGwJI5O NFL2fG0zOzZzNEi5PC=>
MB-453 NVXDOIVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rDdGlEPTB;NkeyJI5O NFK3[I4zOzZzNEi5PC=>
RT-4 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRThzMDDuUS=> MXKyN|YyPDh7OB?=
HOP92 M2HoSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrSTWM2OD16MkCgcm0> MYmyN|YyPDh7OB?=
KG-1 M2mw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITxSFZKSzVyPUmwNEBvVQ>? M{\2[lI{PjF2OEm4
Hs-294T NUDBcWkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrBSlVKSzVyPUm0OUBvVQ>? MWGyN|YyPDh7OB?=
SF-539 M3vhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr0dWlMUUN3ME2xNFAxKG6P NXj1TYYzOjN4MUS4PVg>
U-251 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjVdJRiUUN3ME2xNFAxKG6P MXKyN|YyPDh7OB?=
MB-468 M32xTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHiT|lKSzVyPUGwNFAhdk1? MWSyN|YyPDh7OB?=
HS746T NGS4O3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2njWWlEPTB;MUCwNEBvVQ>? MVeyN|YyPDh7OB?=
SCABER MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3iwVWlEPTB;MUCwNEBvVQ>? NGrFNo8zOzZzNEi5PC=>
MCF-7 NHW5TZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjWU4xKSzVyPUGwNFEhdk1? M3zpNVI{PjF2OEm4
CHL-1 NFX3O5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF2NkCgcm0> NHLFR24zOzZzNEi5PC=>
U87MG M4fkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTtWGNKSzVyPUKwNFAhdk1? NEj6O40zOzZzNEi5PC=>
SJCRH30 NUPRN4dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJyMEKgcm0> MkThNlM3OTR6OUi=
ES-2 NYSyZnhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PqS2lEPTB;Mk[1PUBvVQ>? Mn62NlM3OTR6OUi=
HT-1376 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTlOFhKSzVyPUK4NFAhdk1? MUOyN|YyPDh7OB?=
A172 NHnzTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fFS2lEPTB;M{CwNEBvVQ>? NFHNOmozOzZzNEi5PC=>
769P M2jKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHHTWM2OD1|MECwJI5O M3vFclI{PjF2OEm4
NCI-H520 NHfueHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LPN2lEPTB;M{CwNEBvVQ>? NHjpVngzOzZzNEi5PC=>
DU145 NHXo[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTyN3RXUUN3ME2zNFAxKG6P NX;rO2F2OjN4MUS4PVg>
K562 M3jjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfvbYlKSzVyPUOwNFAhdk1? MnO1NlM3OTR6OUi=
U-937 M3rhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHTTWM2OD1|MECwJI5O MYWyN|YyPDh7OB?=
A204 M4\ue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vmbmlEPTB;M{CwNUBvVQ>? NYPNNGtrOjN4MUS4PVg>
DAOY M37nbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly2TWM2OD1|MECxJI5O MYmyN|YyPDh7OB?=
SF-268 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\0V2lEPTB;M{CwNUBvVQ>? M4XsN|I{PjF2OEm4
SF-295 MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfHTpNKSzVyPUOwNFEhdk1? NXO0[HhrOjN4MUS4PVg>
SNB-19 M1LHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7zelRkUUN3ME2zNFAyKG6P Mn61NlM3OTR6OUi=
SNB-75 NH7QWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e5SGlEPTB;M{CwNUBvVQ>? NUTKNJpXOjN4MUS4PVg>
U373-MG M1fHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3yO5pKSzVyPUOwNFEhdk1? MlzhNlM3OTR6OUi=
786-O MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnlOVJZUUN3ME2zNFAyKG6P MWqyN|YyPDh7OB?=
A498 M{HleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn0TWM2OD1|MECxJI5O NH3DcoEzOzZzNEi5PC=>
ACHN NIKzUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTNyMEGgcm0> NGDDbowzOzZzNEi5PC=>
EKVX MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSz[ZpmUUN3ME2zNFAyKG6P MXeyN|YyPDh7OB?=
H226 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfJendOUUN3ME2zNFAyKG6P M2e3clI{PjF2OEm4
H522 NIjieINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTNyMEGgcm0> NEGxbJUzOzZzNEi5PC=>
HeLa NGXT[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfNd5pKSzVyPUOwNFEhdk1? NXjGfYdWOjN4MUS4PVg>
SK-OV-3 MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nOUGlEPTB;M{CwNUBvVQ>? NVLj[2NnOjN4MUS4PVg>
Ln Cap MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNyMEGgcm0> NFO3fHozOzZzNEi5PC=>
PC3 NYe3Xo5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;HO4hKSzVyPUOwNFEhdk1? NFvncYgzOzZzNEi5PC=>
SNU-16 M4S3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\yTWM2OD1|MECxJI5O MXGyN|YyPDh7OB?=
FTC-133 NX7J[lZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP6cGRKSzVyPUOwNFEhdk1? NX72eHQ2OjN4MUS4PVg>
Ro82-W-1 M4\jd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:2eGlEPTB;M{CwNUBvVQ>? M1iyZ|I{PjF2OEm4
Daudi NWDhTlJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzKSoRKSzVyPUOwNFEhdk1? NUizNWxLOjN4MUS4PVg>
Jijoye NFnifoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITtUFVKSzVyPUOwNFEhdk1? NF3U[HEzOzZzNEi5PC=>
Jurkat NI\rTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTNyMEGgcm0> Mn[xNlM3OTR6OUi=
J-82 M{HsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTNyMEGgcm0> NVW4d|g5OjN4MUS4PVg>
TCC-SUP M2Gzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XTU2lEPTB;M{CwNUBvVQ>? MUSyN|YyPDh7OB?=
BT-474 M4XiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHJZmVKSzVyPUOwNFEhdk1? NHn0XpAzOzZzNEi5PC=>
ZR-75-1 NXvOeoVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPtU2NKSzVyPUOwNFEhdk1? M1iwZ|I{PjF2OEm4

... Click to View More Cell Line Experimental Data

In vivo SCH772984 induces tumor regressions in xenograft models at tolerated doses. SCH772984 effectively inhibites MAPK signaling and cell proliferation in BRAF or MEK inhibitor resistant models. [1]

Protocol

Kinase Assay:

[1]

+ Expand

ERK2 IMAP enzymatic assay:

SCH772984 is tested in 8 point dilution curves in duplicate against purified ERK2 or ERK1. The enzyme is added to the reaction plate. and incubated with the compound before adding a solution of substrate peptide and ATP. 14μl of diluted enzyme (0.3ng active ERK2 per reaction) is added to each well of a 384-well plate. The plates are gently shaken to mix the reagents and incubated for 45 minutes at room temperature. The reaction is stopped with 60μl of IMAP Binding Solution (1:2200 dilutions of IMAP beads in 1X Binding Buffer). The plates are incubated at room temperature for an additional 0.5 hours to allow complete binding of phosphopeptides to the IMAP beads. Plates are read on the LJL Analyst.
Cell Research:

[1]

+ Expand
  • Cell lines: BRAF-mutant or RAS-mutant tumor lines
  • Concentrations: ~10 μM
  • Incubation Time: 5 days
  • Method:

    Cell proliferation experiments are performed in a 96-well format (six replicates), and cells are plated at 4,000/well density. At 24 h after cell seeding, cells are treated with DMSO or 9 point IC50 dilution (0.001-10 μM) at 1% DMSO final for all concentrations. Viability is assayed on 5 days after dosing using ViaLight luminescence kit following the manufacturer’s recommendations. For cell line panel viability assay, cells are treated with SCH772984 for 4 days and assayed by CellTiterGlo luminescent cell viability assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Nude mice
  • Formulation: --
  • Dosages: 12.5 mg/kg, 25 mg/kg, 50 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (23.82 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
0.6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 587.67
Formula

C33H33N9O2

CAS No. 942183-80-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to inhibit Erk1/2 by treating the mice with the inhibitor. by what kind of administration way and at what concentration could it be done?

  • Answer:

    SCH772984 can be administrated by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detail information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

ERK Signaling Pathway Map

Tags: buy SCH772984 | SCH772984 supplier | purchase SCH772984 | SCH772984 cost | SCH772984 manufacturer | order SCH772984 | SCH772984 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID